D. Liénard

2.9k citations

45 papers · 1.8k indexed · h-index 22

Impact in

Dermatology top 1%
- Skin Protection and Aging
Oncology top 5%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research

Papers in ⓘ

Oncology 28
- Cutaneous Melanoma Detection and Management 20
- Cancer Immunotherapy and Biomarkers 4
Dermatology 9
- Skin Protection and Aging 6

Co-authors: Ferdy J. Lejeune (13 shared papers)Philippe Autier (9 shared papers)Alexander M.M. Eggermont (5 shared papers)Ulrich R. Kleeberg (4 shared papers)A.M.M. Eggermont (11 shared papers)Ferdinand Lejeune (5 shared papers)Dirk Schadendorf (5 shared papers)F. Lejeune (7 shared papers)
Journals: Melanoma Research (9 papers)European Journal of Cancer (6 papers)Annals of Oncology (3 papers)International Journal of Cancer (3 papers)World Journal of Surgery (2 papers)
Partner nations: Switzerland Belgium Netherlands

In The Last Decade

D. Liénard

45 papers receiving 1.8k citations

Peers

Countries citing papers authored by D. Liénard

Since Specialization

Citations

This map shows the geographic impact of D. Liénard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Liénard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Liénard more than expected).

Fields of papers citing papers by D. Liénard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Liénard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Liénard. The network helps show where D. Liénard may publish in the future.

Co-authors

The 25 scholars most cited alongside D. Liénard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Liénard Line = papers co-authored together D. Liénard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Sunscreen Use and Duration of Sun Exposure: a Double-Blind, Randomized Trial JNCI Journal of the National Cancer Institute ·Philippe Autier, J. F. Doré, Sylvie Négrier, D. Liénard, Renato G. Panizzon, Ferdinand Lejeune, D Guggisberg, Alexander M.M. Eggermont	1999	177
2	Final results of the EORTC 18871/DKG 80-1 randomised phase III trial European Journal of Cancer ·Ulrich R. Kleeberg, Stefan Suciu, E.‐B. Bröcker, D. J. Ruiter, Cécile Chartier, D. Liénard, J.R. Marsden, Dirk Schadendorf, A.M.M. Eggermont	2003	145
3	Melanoma and use of sunscreens: An EORTC case‐control study in germany, belgium and france International Journal of Cancer ·Philippe Autier, Jean‐François Doré, E. Schifflers, Jean‐Pierre Cesarini, Anne Bollaerts, Klaus F. Koelmel, Olaf Gefeller, A. Liabeuf, Ferdy J. Lejeune, D. Liénard, M. Joarlette, P. Chemaly, Ulrich R. Kleeberg	1995	145
4	Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Journal of Clinical Oncology ·Ulrich Keilholz, S.H. Goey, Cornelis J.A. Punt, T. M. Proebstle, R Salzmann, Carmen Scheibenbogen, Dirk Schadendorf, D. Liénard, Alexander Enk, Reinhard Dummer, B. Hantich, Anne-Marie Geueke, Alexander M.M. Eggermont	1997	139
5	Cytolytic T lymphocyte recognition of the immunodominant HLA-A0201-restricted Melan-A/MART-1 antigenic peptide in melanoma The Journal of Immunology* ·Pedro Romero, Nadine Gervois, J. Schneider, Patricia Escobar, Danila Valmori, Christophe Pannetier, Alexander Steinle, Thomas Wölfel, D. Liénard, Vincent Brichard, Aline Van Pel, Francine Jotereau, J.-C. Cerottini	1997	138
6	Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) International Journal of Cancer ·Nathalie Renard, D. Liénard, Laurence Lespagnard, A. M. M. Eggermont, R Heimann, F. Lejeune	1994	127
7	Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: An eortc multicenter case‐control study in Belgium, France and Germany International Journal of Cancer ·Philippe Autier, Jean‐Francois Doré, Ferdy J. Lejeune, Klaus F. Koelmel, O. Geffeler, P. Hille, Jean‐Pierre Cesarini, D. Liénard, A. Liabeuf, M. Joarlette, P. Chemaly, K. Hakim, A. Koeln, Ulrich R. Kleeberg, (unknown)	1994	117
8	Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ; for the treatment of in-transit melanoma metastases Melanoma Research ·D. Liénard, Alexander M.M. Eggermont, Heimen Schraffordt Koops, Bin K. Kroon, G.D.W Towse, S Hiemstra, P.I.M. Schmitz, Julie Clarke, Gerhard Steinmann, F. Rosenkaimer, Ferdy J. Lejeune	1999	112
9	Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. PubMed ·D. Liénard, Eggermont Am, Schraffordt Koops H, Kroon Bb, F. Rosenkaimer, Philippe Autier, Lejeune Fj	1994	84
10	Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. PubMed ·Mikäel J. Pittet, Daniel E. Speiser, D. Liénard, Danila Valmori, Philippe Guillaume, Valérie Dutoit, Donata Rimoldi, Ferdy J. Lejeune, J C Cerottini, Pedro Romero	2001	77
11	Regional therapy of melanoma European Journal of Cancer ·Ferdy J. Lejeune, D. Liénard, Serge Leyvraz, René‐Olivier Mirimanoff	1993	63
12	Melanoma risk and residence in sunny areas British Journal of Cancer ·(unknown), Philippe Autier, J. F. Doré, Olaf Gefeller, J-P. Cesarini, Ferdy J. Lejeune, K. F. Koelmel, D. Liénard, U.R. Kleeberg	1997	51
13	Rationale for using TNFα and chemotherapy in regional therapy of melanoma Journal of Cellular Biochemistry ·Ferdy J. Lejeune, D. Liénard, A.M.M. Eggermont, H. Schraffordt Koops, F. Rosenkaimer, J. Gérain, Joost M. Klaase, Bin K. Kroon, J Vanderveken, P.I.M. Schmitz	1994	44
14	Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours Annals of Oncology ·Manuel Gander, Serge Leyvraz, Laurent A. Décosterd, Marina Bonfanti, Catia Marzolini, Furao Shen, D. Liénard, Lucien Perey, Gennaro Colella, Jérôme Biollaz, Ferdy J. Lejeune, Daniel B. Yarosh, Michael Belanich, Maurizio D’Incalci	1999	40
15	Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments European Journal of Cancer ·U. Keilholz, Peter Martus, Cornelis J.A. Punt, Wim H.J. Kruit, G. Mooser, Dirk Schadendorf, D. Liénard, R. Dummer, Josef Koller, Christiane Voit, Alexander M.M. Eggermont	2002	39
16	Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. PubMed ·Pierre‐Yves Dietrich, Paul R. Walker, Anne‐Lise Quiquerez, Gaëlle Perrin, Valérie Dutoit, D. Liénard, Philippe Guillaume, J C Cerottini, Pedro Romero, Danila Valmori	2001	38
17	Cutaneous malignant melanoma and exposure to sunlamps and sunbeds Melanoma Research ·Philippe Autier, M. Joarlette, F. Lejeune, D. Liénard, Josette André, G Achten	1991	36
18	Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952 European Journal of Cancer ·Marna G. Bouwhuis, Stefan Suciu, W. Kruit, François Salès, Konstantin Stoitchkov, Poulam M. Patel, V. Cocquyt, José Thomas, D. Liénard, A.M.M. Eggermont, G. Ghanem	2010	34
19	A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities European Journal of Cancer ·Joost M. Klaase, B.B.R. Kroon, Alexander Eggermont, Albertus N. van Geel, H. Schraffordt Koops, J Oldhoff, D. Liénard, Ferdy J. Lejeune, Renée van Berkel, H. R. Franklin, Andrew Hart	1995	30
20	Effects of recombinant tumour necrosis factor (rTNF‐α) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF‐α administration in isolated limb perfusions in cancer patients European Journal of Clinical Investigation ·A. J. G. Swaak, D. Liénard, H. Schraffordt Koops, Ferdy J. Lejeune, A.M.M. Eggermont	1993	26

About D. Liénard

D. Liénard is a scholar working on Oncology, Dermatology, Immunology and Allergy, Immunology and Small Animals, having authored 45 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (20 papers), Immunotherapy and Immune Responses (14 papers), Melanoma and MAPK Pathways (7 papers), Skin Protection and Aging (6 papers), Allergic Rhinitis and Sensitization (4 papers), T-cell and B-cell Immunology (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Sarcoma Diagnosis and Treatment (4 papers). The work is most often cited by research in Dermatology (491 citations), Oncology (973 citations), Immunology (652 citations), Immunology and Allergy (127 citations) and Cell Biology (159 citations). D. Liénard has collaborated with scholars based in Switzerland, Belgium and Netherlands. Frequent co-authors include Ferdy J. Lejeune, Philippe Autier, Alexander M.M. Eggermont, Ulrich R. Kleeberg, A.M.M. Eggermont, Ferdinand Lejeune, Dirk Schadendorf, F. Lejeune, J. F. Doré and F. Rosenkaimer. Their work appears in journals such as Melanoma Research, European Journal of Cancer, Annals of Oncology, International Journal of Cancer and World Journal of Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact